Fibrogen | 8-K: FY2025 Q3 Revenue: USD 1.076 M

Revenue: As of FY2025 Q3, the actual value is USD 1.076 M.

EPS: As of FY2025 Q3, the actual value is USD -3.25.

EBIT: As of FY2025 Q3, the actual value is USD -4.259 M.

Financial Metrics by Segment

Segment Revenue

• Total revenue from continuing operations for the third quarter of 2025 was $1.1 million, compared to $0.1 million for the third quarter of 2024.

Operational Metrics

• Net loss from continuing operations for the third quarter of 2025 was - $13.1 million, or - $3.25 loss per basic and diluted share, compared to a loss of - $48.3 million, or - $12.01 loss per basic and diluted share, one year ago.
• Loss from operations for the third quarter of 2025 was - $5.4 million, compared to - $47.7 million for the same period in 2024.

Cash Flow

• Cash, cash equivalents, investments, and accounts receivable totaled $121.1 million as of September 30, 2025, providing a cash runway into 2028.

Unique Metrics

• Completed the sale of FibroGen China to AstraZeneca for approximately $220 million, which included $85 million in enterprise value and approximately $135 million in net cash held in China.

Outlook / Guidance

• FibroGen expects its cash, cash equivalents, accounts receivable, and investments to be sufficient to fund operating plans into 2028.
• The company remains on track to file the pivotal Phase 3 clinical trial protocol for roxadustat for the treatment of anemia in patients with LR-MDS and high transfusion burden in the fourth quarter of 2025.